Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased response and the refinement of the initial weighted score in a different dataset of individuals, the updated tipranavir score will doubtlessly be a thorough and user-friendly tool that narrows the gap existing between basic science in HIV-1 resistance to antiretrovirals and daily point-of-care clinical practice. The accuracy of the design and the steps used in its validation represent a milestone in HIV-1 resistance knowledge that should also be applied to other antiretroviral drugs in the future.
HIV type-1 (HIV-1) drug resistance can be acquired through treatment failure or transmitted. Both types of resistance are public health concerns and have the potential to reverse the impressive efficacy of antiretroviral therapy. Individuals with HIV-1 drug resistance face antiretroviral therapy with a lower genetic barrier to resistance, a higher risk of virological failure, and eventually with a higher risk of death [1] [2] [3] .
A complete and sustained suppression of HIV-1 replication is currently the target of antiretroviral therapy, including treatment for patients with advanced multiresistant HIV-1 infection [2] . This unambiguous therapeutic end point necessitates a new framework in which the vast knowledge of drug resistance mutations should be cast [4] .
Resistance testing has become widespread, is mandatory prior to any antiretroviral treatment initiation, can improve treatment outcomes for infected individuals and is a crucial component in antiretroviral drug development [1, 2, 5] . The identification of specific drug resistance mutations in the HIV-1 genome (amino acid differences from wild-type reference sequences, most commonly viruses HXB2 and NL43, and a consensus subtype B reference virus sequence) is a very complicated way of facing a very simple issue: the evaluation of HIV-1 drug resistance [6] . Population genotypic testing can be performed with commercial assay kits or in-house protocols. Because of faster turnaround time, lower price and absence of the need for high-tech investigational laboratories, genotypic tests are preferred over phenotypic tests, and are the standard resistance tests used in clinical practice in most settings.
The interpretation of genotypic drug resistance testing remains challenging [6] . Computerized rules-based algorithms are needed to characterize virus as 'susceptible', 'possibly resistant' or 'resistant' to each antiretroviral drug. The algorithms need to take into account the existence of synergism or antagonism between particular patterns of mutations, thus complicating the interpretation beyond a simple list of mutations. The development of these rule-based algorithms is a difficult and lengthy process, and requires frequent updating [7, 8] . The vast majority of genotypic algorithms are based on data that were obtained using subtype B viruses.
The most commonly used resources are lists of mutations related to resistance with every particular drug [9] . The mutations included have been identified by one or more of the following criteria: in vitro passage experiments or validation of contribution to resistance by using site-directed mutagenesis; susceptibility testing of laboratory or clinical isolates; nucleotide sequencing of viruses from patients in whom the drug is failing; and correlation studies between genotype at baseline and virological response in patients exposed to a drug. Clinicians routinely use these lists as a very helpful resource in their clinical practice.
Weighted genotypic lists are a step toward scientific excellence. Although some outstanding publicly available resources offer systems of scoring for all available antiretroviral drugs [8] , specific weighted genotypic scores have only been developed for tipranavir and etravirine so far [10] [11] [12] . Indeed, the score for tipranavir was the first among all antiretrovirals to include mutations associated with increased susceptibility, which grant negative points in the final score. These scores represent valuable and straightforward pocket resources used to maximize the virological response in complicated cases, thus narrowing the gap existing between HIV-1 resistance knowledge and the point of clinical care, and are therefore very helpful for clinicians.
Many genotypic resistance mutation scores have been developed for tipranavir. Since the early list of mutations validated during initial drug development and the RESIST studies [13, 14] , the International AIDS Society-USA, public (Stanford HIVDR) and private (MonogramBio) companies, the French ANRS Society and the Division of Antiviral Products at the US Food and Drug Administration, among others, have validated their own adapted lists of tipranavir-related mutations [5, [15] [16] [17] [18] . Mutations 33F, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 82L/T and 84V were retained in most lists. Those residues closest to tipranavir when bound into the active site of the protease (47V, 82L/T, 83D and 84V) have been retained in most scores [13] . As expected, discrepancy exists regarding some mutations among the different scores, particularly concerning those residues distributed throughout most of the protease structure (encompassing the active site, the extended flap and the cheek area).
The main limitation of these unweighted scores is that all mutations are considered as having equal importance. Thus, the main goal for developing a weighted genotypic score for tipranavir has been to provide clinicians with additional information regarding which mutations have the largest effect on virological response. The initial weighted score presented in 2007 was validated in a dataset of 745 patients treated with tipranavir, who were included in the RESIST studies [12] . The authors used week 8 (≥1 log 10 decrease in HIV RNA), and weeks 24 and 48 (HIV-1 RNA<50 copies/ml) virological response adjusted for background drug activity to validate their data. Using multiple linear regression models, the mutations at the codons 10V, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 74P, 82L/T, 83D and 84V were retained in the final score, whereas 24I, 50L/V, 54L and 76V were associated with increased response (that is, they received negative weights). The greatest weights were granted to a few existing mutations (47V, 54A/M/V, 58E, 74P, 82L/T and 83D), most of which were uncommon in patients who have not used tipranavir. The weighted score showed a strong association with tipranavir phenotype, and also with short-term response and long-term response in the RESIST studies. The authors validated clinical cutoffs to interpret the final score obtained as ≤3 fully sensitive, 4-10 partially sensitive and ≥11 resistant. The authors then strengthened their findings by comparing the clinical performance of their weighted list with the remaining scores on a group of patients who were independent to those used to develop this score [19] . Effectively, the weighted score consistently outperformed the remaining scores in the prediction of week 48 viral load <50 copies/ml in the dataset. The authors warned that their weighted score would need further validation using an external dataset consisting of treatmentexperienced patients with different treatment histories and background regimens other than those included in the RESIST studies.
In the current issue of Antiviral Therapy, Schapiro et al. [20] report a new fine-tuned version of their previous tipranavir weighted genotypic resistance score. They used a set of cohort patients external to the tipranavir Phase III development programme, which was used to validate the initial weighted score. Briefly, they included patients recruited into the BI 1152.51 pharmacokinetic trial (that had mutations at ≥3 of positions 33, 82, 84 and 90), as well as those included in the Italian Cohort, who had access to optimized background regimens with a higher activity than those recruited into the RESIST trial. The final weights retained into the new score were: 74P, 82L/T, 83D and 47V (+4), 58E and 84V (+3), 36I, 43T and 54A/M/V (+2), 10V, 33F and 46L (+1), 24I and 76V (-2), 50L/V (-4) and 54L (-6). Indeed, only mutations 33F (from 0 to +1), 47V (from +6 to +4), 54A/M/V (from +3 to +2), 54L (from -7 to -6), 58E (from +5 to +3), 74P (from +6 to +4), 82L/T (from +5 to +4) and 84V (from +2 to +3) were refined; therefore, mutations conferring >4 points (58E, 74P and 82L/T) have been down-regulated and now grant ≤4 points. Thus, complete tipranavir resistance can not be attained with only two mutations in the score. This new weighted score was more predictive of response than all compared scores across multiple sources of data for all end points when pairwise comparisons of all scores were made [21] . This final validation against other commonly used scores is welcomed by those clinicians tempted to doubt any new proposal at a given time. Effectively, the new weighted score is more accurate than the previous one in predicting virological response to tipranavir, something not unexpected, as experience with the drug accumulates and the new information must be incorporated into the scores.
Although tipranavir is not currently a commonly used protease inhibitor, the methodology used by the authors in the development of their weighted score represents a milestone in HIV-1 resistance knowledge. The accuracy of the design, steps used and validation of the present fine-tuned genotypic weighted resistance score can be applied to any other antiretroviraland particularly with protease inhibitors -and merits the greatest recognition. This is a thorough and userfriendly tool that narrows the gap existing between complicated and sophisticated studies of basic HIV-1 resistance science and its translation into routine point-of-care clinical practice.
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